Department of immunology and microbiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medica Sciences, Tehran, Iran.
Diagn Microbiol Infect Dis. 2024 Feb;108(2):116105. doi: 10.1016/j.diagmicrobio.2023.116105. Epub 2023 Nov 2.
This study aims to investigate the development of secondary bacterial infection and risk factors associated with it in critical COVID-19 patients, and to identify the most common pathogen groups in them. All the cohort studies were retrieved from Scopus, Google Scholar, Web of Science, and MEDLINE from the inception of COVID-19 to 2022 for the following keywords: 'Klebsiella" AND "COVID-19". The most common comorbidities among the patients with COVID-19 were respiratory disease (33.62%), obesity (28.99%), and heart disease or cardiovascular disease (16.31%). We report 42.91% rate of Klebsiella spp co-infection in ICU admission patients, mostly related to K. pneumonia (26.81%), K. aerogenes (9.4%), and K. oxytoca (6.7%). The overall incidence of bacterial infection in hospitalized COVID-19 patients is estimated at 15.5% and in 32.5% of cases of co-infection patients deceased. The threat of carbapenem-resistant K. pneumoniae infections in patients with COVID-19 is imminent, therefore rational antibiotic therapy based on antibiotic sensitivity test should be implemented.
本研究旨在调查重症 COVID-19 患者继发性细菌感染的发展情况及其相关的危险因素，并确定其最常见的病原体群。所有的队列研究均从 Scopus、Google Scholar、Web of Science 和 MEDLINE 数据库中检索，时间范围为 COVID-19 出现至 2022 年，检索词为“Klebsiella”和“COVID-19”。COVID-19 患者最常见的合并症是呼吸道疾病（33.62%）、肥胖症（28.99%）和心脏病或心血管疾病（16.31%）。我们报告 ICU 入院患者中肺炎克雷伯菌合并感染率为 42.91%，主要与肺炎克雷伯菌（26.81%）、产酸克雷伯菌（9.4%）和催产克雷伯菌（6.7%）有关。住院 COVID-19 患者的细菌感染总发生率估计为 15.5%，在合并感染患者中，32.5%的患者死亡。COVID-19 患者中耐碳青霉烯类肺炎克雷伯菌感染的威胁迫在眉睫，因此应根据抗生素敏感性试验实施合理的抗生素治疗。
Zotero 插件